Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Summary

This phase II trial is studying how well erlotinib works in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

Timeline

Start

2003-05

Primary completion

2007-05

Completion

—

Drugs

Indications